With the objective of applying an alternative model for drug research and development for the most neglected diseases, at DNDi we strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do, internally and programmatically. DNDi’s Board of Directors approves project selection and sets policies governing intellectual property, financial control, and ethics.
All of DNDi’s clinical programmes are guided by international, regional, and local regulations and standards, including Good Clinical Practice guidelines (GCP/ICH) and the Helsinki Declaration , following the basic principles for medical research involving human subjects, and according to the local and external institutional review boards, and local rules and regulations of the countries in which we work.
Conflict of Interest Policy
Fraud & Corruption Prevention Policy
Guidelines for the Prevention of Sexual Misconduct
Guiding Principles on the Sharing of Clinical Trial Data
Intellectual Property Policy
Research Misconduct Policy
Safeguarding Dispute Resolution Processes